National Heart Centre Singapore and Duke-National University of Singapore, Singapore.
University Medical Centre Groningen, Groningen, The Netherlands.
J Chin Med Assoc. 2019 Jun;82(6):447-451. doi: 10.1097/JCMA.0000000000000102.
Heart failure (HF) is a growing challenge in the Asia Pacific region. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a well-established tool for diagnosis of HF; however, it is relatively underutilized in predicting adverse outcomes in HF. Multiple studies have demonstrated the prognostic role of NT-proBNP in HF. A single value of NT-proBNP >5000 pg/mL predicts a worse outcome in hospitalized patients with HF with reduced ejection fraction (HFrEF). In stable outpatients with HFrEF, NT-proBNP > 1000 pg/mL predicts a poorer prognosis. NT-proBNP provides the same prognostic information in patients with HF with preserved ejection fraction (HFpEF) as in those with HFrEF. An expert panel composed of cardiologists mainly from Asia Pacific region was convened to discuss the utility of NT-proBNP in HF prognostication. This article summarizes available scientific evidence and consensus recommendations from the meeting.
心力衰竭（HF）是亚太地区日益严峻的挑战。N 末端脑利钠肽前体（NT-proBNP）是诊断 HF 的成熟工具；然而，它在预测 HF 不良结局方面的应用相对较少。多项研究表明 NT-proBNP 在 HF 中的预后作用。在射血分数降低的心力衰竭（HFrEF）住院患者中，NT-proBNP 单次值>5000pg/ml 预示着更差的结局。在射血分数保留的心力衰竭（HFpEF）稳定门诊患者中，NT-proBNP>1000pg/ml 预示着预后更差。NT-proBNP 在 HFpEF 患者中的预后信息与 HFrEF 患者相同。一个由主要来自亚太地区的心脏病专家组成的专家小组被召集来讨论 NT-proBNP 在 HF 预后预测中的应用。本文总结了会议的现有科学证据和共识建议。
